National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
NCT Number: NCT00001154
Researchers plan to study the fat-rich particles, called lipoproteins, which circulate in the blood. This study is designed to improve understanding of normal, as well as abnormal, lipoprotein metabolism and the role it plays in the development of hardening of the arteries (atherosclerosis).
Patients participating in this study will receive injections of lipoproteins or apolipoproteins (the protein component of lipoproteins) that have been isolated and purified. These lipoproteins will be labeled with small amounts of radioactive material and sterilized before they are injected into the patient.
Patients participating in the study will be required to have blood samples taken, and provide urine samples throughout the course of the study. In addition, patient will be required to follow a specially formulated diet. Patients will be weighed throughout the course of the study.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Observational
Bethesda, Maryland, 20892, United States
We propose to investigate human in vivo lipoprotein metabolism using radiolabeled apolipoproteins on plasma lipoproteins. Paired kinetic studies using dual-labeled iodinated lipoproteins and apolipoproteins are performed in healthy volunteer controls with normal lipids and subjects with dyslipidemia under controlled metabolic conditions. Studies are designed to formulate metabolic pathways in patients with undefined genetic disorders of lipid metabolism as well as in healthy volunteers to provide original insights into normal and pathologic metabolic pathways. All kinetic data is computer analyzed to provide quantitative data and facilitate direct comparison of multiple studies.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Subjects with new and undefined dyslipidemia-particularly familial disorders with extreme phenotypes.
Healthy normal volunteers - (18 years old or older) controls to investigate the formation of HDL for prebeta HDL.
Euthyroid.
Exclusion criteria
Healthy control volunteers are initially screened for secondary causes of hyperlipidemia and are excluded if they have any clinically significant laboratory abnormality (i.e., liver disease, disease, kidney disease, endocrine disease,), chronic medical problems (i.e., hypertension, migraines, inflammatory bowel, hepatitis, HIV) or require any chronic medications (i.e., acne, asthma).
The healthy control volunteers weight must fall within the current guidelines for ideal body weight.
Pregnant women.
Unwilling to follow metabolic diet.
Allergic to iodine.
Unable to sign consent form.
Time frame: 5 years
Dyslipidemia
National Heart, Lung, and Blood Institute (NHLBI)
Nih
Lipoprotein Metabolism in Normal Volunteers and Hyperlipoproteinemic Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00362180
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Amsterdam, Netherlands
View Trial DetailsNCT00298909
Cardiovascular Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Leipzig, Germany
View Trial DetailsNCT01569867
Dyslipidemia, Dyslipidemias
Columbus, Ohio, United States
View Trial DetailsNCT00109603
Blood-Borne Infections, Communicable Diseases
Los Angeles, California, United States
View Trial Details